The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer
Elena Castro, Christos Mikropoulos, Elizabeth K Bancroft, Tokhir Dadaev, Chee Goh, Natalie Taylor, Edward Saunders, Nigel Borley, Diana Keating, Elizabeth C Page, Sibel Saya, Stephen Hazell, Naomi Livni, Nandita deSouza, David Neal, Freddie C Hamdy, Pardeep Kumar, Antonis C Antoniou, Zsofia Kote-Jarai, Rosalind A Eeles
ONCOLOGIST | WILEY | Published : 2016
BACKGROUND: A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of PrCa to investigate the probability of detecting PrCa at prostate biopsy (PB). The primary aim of this pilot study was to determine the safety and feasibility of PrCa screening using transrectal ultras..View full abstract
Awarded by Cancer Research UK
Awarded by Genetic Associations and Mechanisms in Oncology (GAME-ON) Initiative (NIH ELLIPSE Grant)
Awarded by European Community's Seventh Framework Programme
Awarded by Cancer Research U.K.
Awarded by NIH
Awarded by Post-Cancer Genome-Wide Association Study Initiative
Awarded by Department of Defense
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Awarded by NATIONAL CANCER INSTITUTE
We thank all the participants and families who took part in this research. This work was supported by The Ronald and Rita McAulay Foundation and Cancer Research UK Grant C5047/A13232. E.C. was supported by a European Society for Medical Oncology Clinical Research Fellowship, and the American Society of Clinical Oncology (ASCO) Cancer Foundation awarded her a 2013 ASCO Annual Meeting Merit Award. C.G. was supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Initiative (NIH ELLIPSE Grant U19CA148537). A.C.A. is a Cancer Research U.K. Senior Cancer Research Fellow (C12292/A11174). The investigators at The Institute of Cancer Research and The Royal Marsden National Health Service (NHS) Foundation Trust are supported by an NIH research grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Funding for the iCOGS infrastructure came from the European Community's Seventh Framework Programme under Grant 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research U.K. (Grants C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the NIH (Grant CA128978), and the Post-Cancer Genome-Wide Association Study Initiative (Grants 1U19 CA148537, 1U19 CA148065, and 1U19 CA148112- the GAME-ON initiative), the Department of Defense (Grant W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The PROFILE Study Steering Committee: A. Ardern-Jones, Royal Marsden NHS Foundation Trust; P. Ardern-Jones, Patient representative; N. van As, Royal Marsden NHS Foundation Trust; D. Dearnaley, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research; C. Foster, HCA Laboratories; V. Khoo, Royal Marsden NHS Foundation Trust; S. Lewis, University of Bristol; H. Lilja, Memorial Sloan Kettering Cancer Center, Lund University, and the University of Oxford; J. Melia, University of Cambridge; C. Moynihan, The Institute of Cancer Research, P. Pharoah, University of Cambridge; and A. Sohaib, Royal Marsden NHS Foundation Trust. E.C. is currently affiliated with the Spanish National Cancer Research Centre, Madrid, Spain.